Metabolic & obesity · Phase I Pipeline

Quick answer

Metabolic & obesity Phase I programs: NovaPharmaNews indexes 148 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 1 of 4

01-DAP-BIO-24

Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

intended for treatment of for the treatment of (2): • insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. • symptomatic chronic heart failure. • chronic kidney disease.

phase 1 other active

1 trial
01API2024

Lacuna Pharma Pty Ltd

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

phase 1 other active

1 trial
02API2024

Lacuna Pharma Pty Ltd

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

phase 1 other active

1 trial
14028 injection

Sunshine Guojian Pharmaceutical (Shanghai) Co.,

Type 2 Diabetes

phase 1 mab completed

1 trial
1404-0008

Boehringer Ingelheim

Overweight, Obesity

phase 1 other active

1 trial
14040047

Boehringer Ingelheim

No targeted indication. Male and female subjects with obesity.

phase 1 other active

1 trial
1458-0006

Boehringer Ingelheim

Obesity

phase 1 other active

1 trial
1524-0001

Boehringer Ingelheim

Metabolic Dysfunction-associated Steatohepatitis

phase 1 other active

1 trial
15403/23-24

BRIGHT MINDS BIOSCIENCES INC.

Diabetes Mellitus, Type 2

phase 1 small molecule active

1 trial
300 mg LX4211 (150 mg tablets)

LEXICON PHARMACEUTICALS, INC.

Type 2 Diabetes Mellitus

phase 1 small molecule completed

1 trial
400 mg LX4211

LEXICON PHARMACEUTICALS, INC.

Type 2 Diabetes Mellitus

phase 1 small molecule completed

1 trial
A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity

Elan Pharma International

Adults Living with Overweight and Obesity

phase 1 other active

1 trial
A research study of a new medicine (NNC0650-0013) in healthy men

NovoThirteen

Weight management, Diabetes mellitus type 2; healthy subjects

phase 1 other active

1 trial
A study of how CagriSema works on appetite in people with excess body weight

NovoThirteen

Obesity

phase 1 other active

1 trial
ALG-055009

Aligos Therapeutics

NASH - Nonalcoholic Steatohepatitis

phase 1 small molecule completed

1 trial
ALN-PNP

Regeneron UK Limited

Nonalcoholic Fatty Liver Disease (NAFLD)

phase 1 small molecule completed

1 trial
ALT-801

Timmune Biotech

Obesity

phase 1 small molecule completed

1 trial
ALY688ER-101

Lacuna Pharma Pty Ltd

NASH

phase 1 other active

1 trial
Administration of UI087

United Therapeutics Europe Ltd

Diabetes Mellitus (Type 2)

phase 1 small molecule active

1 trial
Aramchol

Galmed Pharmaceuticals

NASH

phase 1 small molecule completed

1 trial
Autologous differentiated myocyte transplantation

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Metabolic Disease

phase 1 mab active

1 trial
BCX7353 and probes

Biocryst

Hereditary Angioedema

phase 1 small molecule completed

1 trial
BP45670

Hoffmann-La Roche

Type 2 Diabetes and obesity

phase 1 other active

1 trial
BP45800

Hoffmann-La Roche

Obesity or Overweight

phase 1 other active

1 trial
BP45910

Hoffmann-La Roche

Healthy Overweight or Obese

phase 1 other active

1 trial
BP45980

Hoffmann-La Roche

Type 2 Diabetes Mellitus (T2DM) and overweight or obesity

phase 1 other active

1 trial
C19-A3 GNP

Cardiff Oncology

Type 1 Diabetes

phase 1 small molecule completed

1 trial
C3421063

Pfizer Australia Pty Ltd

Type 2 Diabetes Mellitus, Obesity, Overweight management

phase 1 other active

1 trial
C5541002

Pfizer Australia Pty Ltd

Obesity, Overweight

phase 1 other active

1 trial
CKD-371

Hong Kong Baptist University

Type II Diabetes Mellitus

phase 1 small molecule completed

1 trial
CKD-393 formulation I

Hong Kong Baptist University

Type II Diabetes

phase 1 small molecule completed

1 trial
CM-101

Chemomab Therapeutics

Nonalcoholic Steatohepatitis (NASH)

phase 1 small molecule completed

1 trial
COR1389-101

Lacuna Pharma Pty Ltd

Obesity / Right heart failure (healthy participants)

phase 1 other active

1 trial
CRB-913

Corbus Pharmaceuticals Holdings

Obese But Otherwise Healthy Participants

phase 1 small molecule active

1 trial
CT-996

The First People's Hospital of Lianyungang

Type 2 Diabetes

phase 1 small molecule completed

1 trial
Camel milk containing Bifidobacterium animalis A6

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Type 2 Diabetes

phase 1 other completed

1 trial
D7860C00005

AstraZeneca AB

Type 2 Diabetes Mellitus

phase 1 other active

1 trial
DFUPS

United Therapeutics Europe Ltd

Diabetic Foot

phase 1 other completed

1 trial
DS101-CT-01

The George Institute

Diabetic retinopathy.

phase 1 other active

1 trial
DS101-CT-01

The George Institute

Diabetic retinopathy.

phase 1 other active

1 trial
Dose escalation of SA030

Suzhou Ribo Life Science Co.

Obese

phase 1 small molecule active

1 trial
Drug 601

Sunshine Guojian Pharmaceutical (Shanghai) Co.,

Diabetic Macular Edema

phase 1 small molecule active

1 trial
EDP 305

ENANTA PHARMACEUTICALS INC

NASH

phase 1 small molecule completed

1 trial
EDP 305

ENANTA PHARMACEUTICALS INC

Presumptive NAFLD

phase 1 small molecule completed

1 trial
EDP-297

ENANTA PHARMACEUTICALS INC

NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis

phase 1 small molecule completed

1 trial
EDP-305

ENANTA PHARMACEUTICALS INC

NASH - Nonalcoholic Steatohepatitis

phase 1 small molecule completed

2 trials
EMPAG-05-24

Lacuna Pharma Pty Ltd

Diabetes

phase 1 other active

1 trial
Empagliflozin 10 MG Oral Tablet [Jardiance]

BRIGHT MINDS BIOSCIENCES INC.

Diabetes Mellitus

phase 1 small molecule completed

1 trial

Frequently asked questions

How many metabolic & obesity Phase I programs exist?

148 programs match both the therapeutic area and stage filters in our published index.

Quick answer

Top sponsors

Pipeline programs

01-DAP-BIO-24

01API2024

02API2024

14028 injection

1404-0008

14040047

1458-0006

1524-0001

15403/23-24

300 mg LX4211 (150 mg tablets)

400 mg LX4211

A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity

A research study of a new medicine (NNC0650-0013) in healthy men

A study of how CagriSema works on appetite in people with excess body weight

ALG-055009

ALN-PNP

ALT-801

ALY688ER-101

Administration of UI087

Aramchol

Autologous differentiated myocyte transplantation

BCX7353 and probes

BP45670

BP45800

BP45910

BP45980

C19-A3 GNP

C3421063

C5541002

CKD-371

CKD-393 formulation I

CM-101

COR1389-101

CRB-913

CT-996

Camel milk containing Bifidobacterium animalis A6

D7860C00005

DFUPS

DS101-CT-01

DS101-CT-01

Dose escalation of SA030

Drug 601

EDP 305

EDP 305

EDP-297

EDP-305

EMPAG-05-24

Empagliflozin 10 MG Oral Tablet [Jardiance]

Frequently asked questions

Stay Ahead in Pharma